2026 is framed as a pivotal turning point for the pharmaceutical industry. The market is being reshaped by three concurrent forces: Merck’s Keytruda sustaining its immuno-oncology dominance, the rapid ascent of Eli Lilly and Novo Nordisk’s “diabesity” portfolios redefining the value center of the industry, and the first real financial impact of the U.S. Inflation … [Illustrations] Global Blockbuster Drug Landscape Shifts in 2026: Keytruda Defends No. 1, “Diabesity” Rivals Surge, IRA Price Caps Take Effect Read More » To access this post, you must purchase Individual Subscriber Yearly or Enterprise Subscriber.